Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system
Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application.